Trinity Biotech Net Income From Continuing Ops Over Time
| TRIB Stock | USD 0.77 0.00 0.000003% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Trinity Biotech Performance and Trinity Biotech Correlation. Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Trinity Biotech. If investors know Trinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Trinity Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.77) | Earnings Share (1.80) | Revenue Per Share | Quarterly Revenue Growth 0.181 | Return On Assets |
Trinity Biotech plc's market price often diverges from its book value, the accounting figure shown on Trinity's balance sheet. Smart investors calculate Trinity Biotech's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Trinity Biotech's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Please note, there is a significant difference between Trinity Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Trinity Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Trinity Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income From Continuing Ops Analysis
Compare Trinity Biotech plc and related stocks such as Advanced Biomed Common, BioNexus Gene Lab, and Beyond Air Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ADVB | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (1.8 M) | (4 M) | (3.7 M) | (2.8 M) | (2.8 M) | (2.5 M) | (2.6 M) |
| BGLC | 26.5 K | 26.5 K | 26.5 K | 26.5 K | 26.5 K | 26.5 K | 26.5 K | 26.5 K | 26.5 K | (246.5 K) | 1.4 M | 795.1 K | (356 K) | (3.1 M) | (1.6 M) | (1.4 M) | (1.4 M) |
| XAIR | (29.7 K) | (29.7 K) | (29.7 K) | (29.7 K) | (29.7 K) | (29.7 K) | (68.2 K) | (18 M) | (6.6 M) | (19.9 M) | (22.9 M) | (44.1 M) | (59.4 M) | (64.3 M) | (48.5 M) | (43.6 M) | (45.8 M) |
| MRKR | 1.5 M | 1.5 M | 1.5 M | 1.5 M | (30.3 M) | (6.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (24.5 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| SINT | (32.6 M) | (32.6 M) | (32.6 M) | (32.6 M) | (32.6 M) | (23.9 M) | (14.8 M) | (9.3 M) | (9.7 M) | (4.8 M) | (7 M) | (8.8 M) | (12 M) | (9.9 M) | (11 M) | (12.7 M) | (13.3 M) |
| EVGN | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (19.1 M) | (26.2 M) | (30.4 M) | (29.8 M) | (22.4 M) | (18.1 M) | (16.2 M) | (17.1 M) |
| SNSE | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (16.7 M) | (20.1 M) | (36.8 M) | (48.6 M) | (38.9 M) | (30.2 M) | (27.1 M) | (28.5 M) |
| TNON | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (705.4 K) | (7.1 M) | (18.9 M) | (20.4 M) | (13.7 M) | (12.3 M) | (12.9 M) |
Trinity Biotech plc and related stocks such as Advanced Biomed Common, BioNexus Gene Lab, and Beyond Air Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Trinity Biotech plc | TRIB |
Specialization | Health Care, Health Care Equipment & Services |
| Business Address | IDA Business Park, |
| Exchange | NASDAQ Exchange |
USD 0.77
Check out Trinity Biotech Performance and Trinity Biotech Correlation. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Trinity Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.